LXRX
Lexicon Pharmaceuticals Inc
1.80$
+0.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 4.3% | 2,112.8% | 15.5% | 10.1% | 4.1% | 97.7% | 2.4% | 0.7% | 0.1% | 5.8% | 0.5% | 5.6% | 1.1% | |
| 95.7% | -2,012.8% | 84.5% | 89.9% | 95.9% | 2.3% | 97.6% | 99.3% | 99.9% | 94.2% | 99.5% | 94.4% | 98.9% | |
| 10,838.3% | 2,102.8% | 1,259.1% | 1,071.2% | 1,473.1% | 100.5% | 1,212.6% | 53.9% | 132.3% | 203.8% | 60.4% | 2,520.7% | 145.1% | |
| 1,580.9% | 4,954.6% | 2,837.2% | 2,379.6% | 2,262.4% | 121.5% | 919.8% | 32.4% | 53.6% | 159.4% | 43.8% | 1,409.0% | 85.2% | |
| 30,732.1% | 4,644.9% | 4,096.3% | 3,450.8% | 3,735.5% | 125.6% | 2,132.4% | 86.3% | 185.9% | 363.3% | 104.2% | 3,929.6% | 230.3% | |
| -30,636.4% | -6,657.7% | -4,011.8% | -3,360.9% | -3,639.6% | -123.3% | -2,034.8% | 12.9% | -85.9% | -269.1% | -4.7% | -3,835.3% | -131.4% | |
| 2,406.8% | 772.2% | 437.9% | 134.2% | 260.7% | 14.5% | 145.4% | 8.0% | 15.2% | 37.0% | 7.5% | 377.0% | 20.2% | |
| -31,188.3% | -7,087.7% | -4,282.9% | -3,244.0% | -3,703.5% | -127.2% | -2,004.4% | 11.3% | -90.0% | -282.7% | -4.9% | -4,591.8% | -147.4% | |
| 1,761.7% | -424.1% | 8.9% | – | – | -0.4% | – | – | – | – | – | – | – | |
| -31,188.3% | -7,087.7% | -4,282.9% | -3,244.0% | -3,703.5% | -127.2% | -2,004.4% | 11.3% | -90.0% | -282.7% | -4.9% | -4,591.8% | -147.4% | |
| -28,688.3% | -6,431.6% | -3,933.9% | -3,101.3% | -3,435.6% | -76.5% | -1,845.0% | 19.9% | -73.8% | -243.6% | 3.1% | -4,200.0% | -126.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.